多中心健康系统登记中心力衰竭患者呼吸道疫苗的接种情况
本研究为观察性研究,利用美国南加州某整合型多中心学术健康系统2019至2022年数据,纳入5089例成人心力衰竭患者,采用逻辑回归分析流感、肺炎球菌和COVID-19疫苗接种率及与心衰表型的关系。结果显示,接种率分别为流感疫苗58.0%、肺炎球菌疫苗76.2%、COVID-19疫苗83.3%;校正模型中,射血分数降低的心衰(HFrEF)患者相比射血分数保留的心衰(HFpEF)患者,上述三种疫苗的接种几率均更低。
要点
- 5089例心衰患者中,流感疫苗接种率58.0%、肺炎球菌疫苗76.2%、COVID-19疫苗83.3%。
- HFrEF患者流感、肺炎球菌、COVID-19疫苗接种几率均低于HFpEF患者。
- 接种状态在年龄、种族/族裔、保险类型、ACO成员、主要语言、SVI评分、临床医生类型和合并症数量上存在差异。
核心结论
- 与其他特定心衰类别相比,HFrEF患者的呼吸道疫苗接种水平最低。
- 需要开展干预以提高疫苗接种教育和提供机会,尤其是针对HFrEF患者。
研究设计与样本
- 观察性研究,使用美国南加州某整合型多中心学术健康系统2019至2022年数据,纳入5089例成人心力衰竭患者。
- 采用逻辑回归模型分析流感、肺炎球菌和COVID-19疫苗接种率,并判断心衰表型是否与接种状态相关。
主要发现
- 5089例心衰患者中,58.0%接种流感疫苗,76.2%接种肺炎球菌疫苗,83.3%接种COVID-19疫苗。
- 接种状态无性别差异;在年龄、种族/族裔、保险类型、是否为ACO成员、主要语言、SVI评分、临床医生类型和合并症数量方面存在差异。
- HFpEF和HFmrEF患者的接种率高于HFrEF患者。
- 校正模型中,相比HFpEF患者,HFrEF患者接种流感疫苗的aOR=0.75(95%CI=0.66-0.86)、肺炎球菌疫苗的aOR=0.65(95%CI=0.55-0.75)、COVID-19疫苗的aOR=0.74(95%CI=0.62-0.89)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heart failure affects people of all ages and is a leading cause of death for both men and women in most racial and ethnic groups in the United States. Infections are common causes of hospitalizations in heart failure, with respiratory infections as the most frequent diagnosis. Vaccinations provide significant protection against preventable respiratory infections. Despite being an easily accessible intervention, prior studies suggest vaccines are underused in patients with heart failure. METHODS: An observational study of 5089 adults with heart failure was conducted using data from an integrated, multicenter, academic health system in Southern California from 2019 to 2022. Logistic regression models were used to determine the rates of influenza, pneumococcal, and COVID-19 vaccination among a population of patients with heart failure (heart failure preserved ejection fraction [HFpEF], heart failure mildly reduced ejection fraction [HFmrEF], and heart failure reduced ejection fraction [HFrEF], and identify whether heart failure phenotype is associated with vaccination status. RESULTS: Vaccination rates varied between influenza, pneumococcal, and COVID-19 vaccines. Of the three respiratory vaccines, 58.0 % of patients had received an influenza vaccine, 76.2 % had received a pneumococcal vaccine, and 83.3 % had received a COVID-19 vaccine. There were no sex-based differences by vaccination status. Differences were seen within age, race/ethnicity, insurance type, whether the patient was a member of an Accountable Care Organization (ACO), primary language, Social Vulnerability Index (SVI) score, clinician type, and number of comorbidities. Patients with HFpEF and HFmrEF had higher vaccination rates than HFrEF. In adjusted models, patients with HFrEF had lower odds of being vaccinated for influenza (aOR = 0.75, 95 % CI = 0.66-0.86), pneumococcal (aOR = 0.65, 95 % CI = 0.55-0.75), and COVID (aOR = 0.74, 95 % CI = 0.62-0.89) compared to patients with HFpEF. CONCLUSIONS: Patients with HFrEF had the lowest levels of respiratory vaccination compared to other specified heart failure categories. Interventions are needed to increase vaccination education and offerings, especially to patients with HFrEF.
引用
- Dermenchyan A, Choi KR, Bokhoor PR, et al. Receipt of respiratory vaccines among patients with heart failure in a multicenter health system registry. Vaccine. 2025. PMID: 39746280. doi:10.1016/j.vaccine.2024.126682
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。